Reirrradiation

Monday

May 05

17:00 - 18:00

Strauss 1-2

Genito-urinary 1

Co-Chair: Alessandra Castelluccia, Italy;

Chair: Ghaiet El Fida Noubbigh, Tunisia

Overview: Proffered Papers are presented in one of the sessions scheduled in the main session halls. Each author will present orally for 7 minutes, followed by 3 minutes for discussion. Sessions will be recorded and available on-demand.

Session Type: Proffered Papers

Track: Clinical

Journey:

17:00 - 17:10

Outcomes of SBRT for PSMA PET diagnosed hormone-sensitive oligorecurrent prostate cancer: results from a large international multi-center cohort

Presenter: Timo Soeterik, The Netherlands

Presentation Number: E25-1859

17:10 - 17:20

Exploring predictive factors for late urinary toxicity after prostate SBRT: Findings from the PACE-B Study

Presenter: Ragu Ratnakumaran, United Kingdom

Presentation Number: E25-2750

17:20 - 17:30

Is hypofractionated whole-pelvis RT (WPRT) as well tolerated as conventional WPRT in prostate cancer? Analysis of the Hope trial primary endpoint

Presenter: Lucas Mendez, Canada

Presentation Number: E25-1634

17:30 - 17:40

Impact of staging PSMA-PET/CT on radiotherapy planning in men with high-risk prostate cancer – results of a prospective multicenter randomized trial

Presenter: Stefan Alexander Koerber, Germany

Presentation Number: E25-3984

17:40 - 17:50

Long-term urinary continence and influencing factors after salvage radiotherapy: Results of the SAKK 0910 dose escalation trial

Presenter: Christina Schröder, Switzerland

Presentation Number: E25-1699

17:50 - 18:00

Preliminary results of a phase II randomized control trial of neurovascular-sparing SAbR in localized prostate cancer [PCa] (POTEN-C, NCT03525262)

Presenter: Neil Desai, USA

Presentation Number: E25-1650

ESTRO 2025

Session